نتایج جستجو برای: platinum compounds

تعداد نتایج: 246783  

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2016
S Hager C J Ackermann M Joerger S Gillessen A Omlin

BACKGROUND For men with advanced castration-resistant prostate cancer (CRPC), several treatment options are available, including androgen receptor (AR) pathway inhibitors (abiraterone acetate, enzalutamide), taxanes (docetaxel, cabazitaxel) and the radionuclide (radium-223). However, cross-resistance is a clinically relevant problem. Platinum compounds have been tested in a number of clinical t...

2010
Ulrike Olszewski Thomas Tuxen Poulsen Ernst Ulsperger Hans Skovgard Poulsen Klaus Geissler Gerhard Hamilton

PURPOSE Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase (PDK), and thus promotes glucose oxidation over glycolysis and induces apoptotic death of tumor cells. The present study investigated the potential of DCA to increase the antitumor effects of platinum- based compounds against a panel of permanent cell lines, including small cell lung cancer (SCLC), ovarian cancer, and Ewing's ...

Journal: :Anticancer research 2004
Bernard Desoize

Metals and metal compounds have been used in medicine for several thousands of years. In this review we summarized the anti-cancer activities of the ten most active metals: arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium and platinum. The first reviewed metal, arsenic, presents the anomaly of displaying anti-cancer and oncogenic properties simultaneously. Some antim...

2012
Osamu Ege Hisao Negita

für Naturforschung in cooperation with the Max Planck Society for the Advancement of Science under a Creative Commons Attribution 4.0 International License. Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namen...

2018
Ewa Wagner-Wysiecka Natalia Łukasik Jan F. Biernat Elżbieta Luboch

In the original publication of the article, a part of Scheme 12 was missed. The correct version of Scheme 12 was provided in this correction article. The original article has also been corrected. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, ...

2008
V. I. SPITSYN

The report involves a review of the most important work on coordination chemistry carried out in the Soviet Union during this decade in the field of platinum metals, rare earth elements, actinides, as well as complex compounds of elements from various groups of the D. I. Mendeleev Periodic System. The results obtained on studying heteropolyacids and complexes with different new types of ligands...

Journal: :Dalton transactions 2009
Yvonne Unger Alexander Zeller Maria A Taige Thomas Strassner

Although examples of nickel(ii), palladium(ii) and platinum(ii) N-heterocyclic tetracarbene complexes are known in the literature, particularly platinum(ii) tetracarbene complexes are rare. We developed a new synthetic route via biscarbene acetate complexes, which make homoleptic as well as heteroleptic platinum(ii) tetracarbene complexes accessible. The reported photoluminescence data show tha...

2009
Ulrike Olszewski Florian Ach Ernst Ulsperger Gerhard Baumgartner Robert Zeillinger Patrick Bednarski Gerhard Hamilton

Platinum(IV) compounds like oxoplatin (cis, cis, trans-diammine-dichlorido-dihydroxido-platinum(IV)) show increased stability and therefore can be applied orally. In a panel of 38 human cancer cell lines this drug induced S-phase arrest and cell death with IC(50) values 2.5-fold higher than cisplatin. Oxoplatin may be converted to cisplatin by intracellular reducing agents, however, exposure to...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2001
M J Piccart H Lamb J B Vermorken

The discovery of cisplatin more than two decades ago was the most important therapeutic advance in the treatment of ovarian cancer. Today, cisplatin or carboplatin in combination with paclitaxel is the most commonly used first-line treatment for patients with advanced ovarian cancer. Although platinum drugs remain a critical component of chemotherapy in this type of cancer, cumulative toxicitie...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید